Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

Core Viewpoint - The OMNI Surgical System demonstrates significant long-term intraocular pressure (IOP) reduction and medication reduction in treating primary open-angle glaucoma, supported by data from a meta-analysis and the IRIS Registry [1][2][4] Group 1: Clinical Effectiveness and Safety - Presentations at the 2025 American Glaucoma Society Annual Meeting will showcase new data on the clinical effectiveness and safety of the OMNI Surgical System across diverse patient populations [1][2] - Data from the IRIS Registry indicates that OMNI, when combined with cataract surgery in Black patients, resulted in significant IOP reductions and decreased medication use over 24 to 36 months [3][4][13] - A systematic review and meta-analysis of 22 studies involving 2,379 eyes concluded that OMNI consistently reduced IOP and medication needs for up to 36 months [6][8] Group 2: Data Sources and Partnerships - The data presented is curated by Verana Health, in partnership with the American Academy of Ophthalmology IRIS Registry, which is one of the largest clinical data registries in medicine [2][4][16] - The IRIS Registry has collected over 851 million patient encounters and 80 million unique de-identified patients from more than 30 electronic health records and 15,000 eye care professionals across the U.S. [4] Group 3: Company Commitment and Future Directions - Sight Sciences emphasizes its commitment to advancing glaucoma care by providing effective treatment options that reduce medication dependence and improve patient quality of life [4][11] - The company aims to transform eye care through innovative interventional technologies, with the OMNI Surgical System being a key product indicated for reducing IOP in adult patients with primary open-angle glaucoma [11][15]